Aspire Biopharma Holdings (ASBP) Change in Account Payables (2022 - 2026)
Aspire Biopharma Holdings' (ASBP) quarterly Change in Account Payables came in at -$139535.0 in Q1 2026, down 112.44% year-on-year from $1.1 million in Q1 2025, and down 199.91% on a QoQ basis from -$46526.0 in Q4 2025.
Aspire Biopharma Holdings (ASBP) Change in Account Payables (2022 - 2026) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 5 years of Change in Account Payables data on file, last reported at -$139535.0 in Q1 2026.
- On a quarterly basis, Change in Account Payables fell 112.44% year-over-year to -$139535.0 in Q1 2026; TTM through Mar 2026 was -$1.6 million, a 176.58% decrease from a year earlier, with the FY2025 full-year figure at -$323776.0, down 135.73% from the prior year.
- Change in Account Payables for Q1 2026 stood at -$139535.0, down from -$46526.0 in the prior quarter.
- Over the last five years, Change in Account Payables for ASBP reached as high as $1.1 million in Q1 2025 and fell as low as -$1.3 million in Q3 2025.
- Historically, Change in Account Payables has averaged $40107.3 across 5 years, with a median of $30000.0 in 2022.
- Across the five-year window, Change in Account Payables soared 3508.21% in 2024 and sank 2219.6% in 2025, its largest moves.
- Year by year, Change in Account Payables stood at $30000.0 in 2022, then retreated by 9.99% to $27002.0 in 2023, then surged by 3508.21% to $974289.0 in 2024, then sank by 104.78% to -$46526.0 in 2025, then plunged by 199.91% to -$139535.0 in 2026.
- Per Business Quant data, the three most recent Change in Account Payables figures were -$139535.0 in Q1 2026, -$46526.0 in Q4 2025, and -$1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,192.35 Bn | 67,192.06 Bn | - | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.52 Bn | 466.73 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.73 Bn | 114.48 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.88 Bn | 61.13 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 63.11 Bn | 63.11 Bn | - | - |
| 8 | Argenx Se | 55.88 Bn | 50.70 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.48 Bn | 37.48 Bn | - | 16.86 Mn |
| 10 | Aspire Biopharma Holdings | 1.10 Mn | -724,996.75 | 5,750.00 | -139,535.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -139,535.00 |
| Mar 31, 2026 | -139,535.00 |
| Dec 31, 2025 | -46,526.00 |
| Dec 31, 2025 | -46,526.00 |
| Sep 30, 2025 | -1.32 Mn |
| Sep 30, 2025 | -1.32 Mn |
| Jun 30, 2025 | -80,386.00 |
| Jun 30, 2025 | -80,386.00 |
| Mar 31, 2025 | 1.12 Mn |
| Mar 31, 2025 | 1.12 Mn |
| Dec 31, 2024 | 974,289.00 |
| Dec 31, 2024 | 974,289.00 |
| Sep 30, 2024 | -56,849.00 |
| Sep 30, 2024 | -56,849.00 |
| Jun 30, 2024 | 30,529.00 |
| Jun 30, 2024 | 30,529.00 |
| Mar 31, 2024 | -41,773.00 |
| Mar 31, 2024 | -41,773.00 |
| Dec 31, 2023 | 27,002.00 |
| Dec 31, 2023 | 27,002.00 |